4.5 Article

Comprehensive assessment of PINK1 variants in Parkinson's disease

Journal

NEUROBIOLOGY OF AGING
Volume 91, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2020.03.003

Keywords

PINK1; Parkinson's disease; p.G411S; Heterozygous carriers; Risk factor

Funding

  1. National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health, Department of Health and Human Services [1ZIA-NS003154, Z01-AG000949-02, Z01-ES101986]
  2. National Institute on Aging (NIA) of the National Institutes of Health, Department of Health and Human Services [1ZIA-NS003154, Z01-AG000949-02, Z01-ES101986]
  3. National Institute of Environmental Health Sciences of the National Institutes of Health, Department of Health and Human Services [1ZIA-NS003154, Z01-AG000949-02, Z01-ES101986]
  4. UK Biobank [33601]
  5. Michael J. Fox Foundation for Parkinson's Research
  6. AbbVie
  7. Avid
  8. Biogen
  9. Bristol-Myers Squibb
  10. Covance
  11. GE Healthcare
  12. Genentech
  13. GlaxoSmithKline
  14. Lilly
  15. Lundbeck
  16. Merck
  17. Meso Scale Discovery
  18. Pfizer
  19. Piramal
  20. Roche
  21. Servier
  22. Teva
  23. UCB
  24. Golub Capital
  25. Michael J. Fox Foundation
  26. Canadian Consortium on Neurodegeneration in Aging (CCNA)
  27. Parkinson Canada
  28. Canada First Research Excellence Fund (CFREF)
  29. Fonds de recherche du Quebec -Sante (FRQS) Chercheursboursiers award

Ask authors/readers for more resources

Multiple genes have been associated with monogenic Parkinson's disease and Parkinsonism syndromes. Mutations in PINK1 (PARK6) have been shown to result in autosomal recessive early-onset Parkinson's disease. In the past decade, several studies have suggested that carrying a single heterozygous PINK1 mutation is associated with increased risk for Parkinson's disease. Here, we comprehensively assess the role of PINK1 variants in Parkinson's disease susceptibility using several large data sets totalling 376,558 individuals including 13,708 cases with Parkinson's disease and 362,850 control subjects. After combining these data, we did not find evidence to support a role for heterozygous PINK1 mutations as a robust risk factor for Parkinson's disease. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available